Log in using OpenID

Hepatic Encephalopathy Market

Hepatic encephalopathy (HE) is a neuropsychiatric complication commonly associated with the liver disease: cirrhosis.
Hepatic Encephalopathy Market - Size, Share,
Outlook, and Opportunity Analysis, 20192027
Hepatic encephalopathy (HE) is a neuropsychiatric complication commonly associated with the
liver disease: cirrhosis. The inability of the liver to metabolize ammonia results in a buildup of
ammonia, which can cross the blood–brain barrier and cause significant neurocognitive
impairment. A significant number of patients with cirrhosis may experience HE and may be at
high risk of recurrent HE.
For In depth Information Get Sample Copy of this Report @
The severity of hepatic encephalopathy can be broadly categorized into two classes: Covert
Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). OHE is associated
with high rates of mortality and hospitalizations and poor quality of life. Factors such as
infections, gastrointestinal bleeding, metabolic disturbance, and dietary protein overload may
cause OHE. According to a study conducted by the U.S. National Library of Medicine in 2016,
30 to 50% of patients who have cirrhosis during their clinical care are likely to develop OHE.
The global hepatic encephalopathy market was valued at US$ 2,408.3 Mn in 2017, and is
expected to witness a CAGR of 6.3% during the forecast period (2018 – 2026).
Market Dynamics
HE is a rare disease. Several drugs are available such as antibiotics, laxatives, probiotics, and
lactulose that aid in the treatment of this disease. Key players in the market are focused on
adopting acquisition strategies to expand their product portfolio. For instance, in December
2017, Mallinckrodt Pharmaceuticals announced acquisition of Ocera Therapeutics, a clinicalstage biopharmaceutical company. Ocera Therapeutics is focused on the development and
commercialization of novel therapeutics for orphan and other severe liver diseases.
Report includes chapters which deeply display the following deliverable about industry :
• Hepatic Encephalopathy Market Research Objective and Assumption
• Hepatic Encephalopathy Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Hepatic Encephalopathy Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Hepatic Encephalopathy Market, By Regions
• Hepatic Encephalopathy Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Hepatic Encephalopathy Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Hepatic Encephalopathy Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Hepatic Encephalopathy Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Increasing number of drugs in pipeline for the treatment of HE is expected to drive the market
growth during the forecast period
There are different types of therapeutic drugs in pipeline for the treatment of HE. Increasing
number of products in pipeline for the treatment of HE is expected to drive growth of the
market over the forecast period.
Inquire Here Before Purchase of Research Report @
Umecrine Cognition, a Sweden-based pharmaceutical company, is developing a therapy that
represents a new target class for several major central nervous system (CNS)-related disorders.
The lead compound GR3027 is presently in clinical development for HE. The company plans to
demonstrate Phase II data of GR3027 for the treatment of HE in 2020.
Key players operating in the global hepatic encephalopathy market include, ASKA
Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences,
Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals
Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Alex Huge
Alex Huge414   documents Email
Health and Medicine
File Size
108 KB
market, Hepatic Encephalopathy Market
Report inappropriate content